Table 2: Stratification analysis ofrisk genotypes and neuroblastoma susceptibility.

Variables⁢rs2228001 (cases/controls)Adjusted ORP⁢rs2228000 (cases/controls)Adjusted OR⁢rs2229090 (cases/controls)Adjusted OR
AAAC/CC(95% CI)CCCT/TT(95% CI)GGGC/CC(95% CI)

Age, month
 ≤1847/10253/1310.87 (0.54–1.39)0.55717/3783/1960.93 (0.49–1.74)0.81143/7957/1540.68 (0.42–1.10)0.119
 >1852/116101/1821.24 (0.82–1.86)0.30417/39136/2591.20 (0.65–2.20)0.55956/11297/1861.04 (0.69–1.55)0.862
Sex
 Females46/9555/1380.81 (0.50–1.30)0.38317/3184/2020.75 (0.39–1.43)0.38237/8964/1441.08 (0.66–1.74)0.771
 Males53/12399/1751.31 (0.87–1.97)0.19017/45135/2531.40 (0.77–2.55)0.27062/10290/1960.75 (0.50–1.13)0.167
Sites of origin
 Adrenal gland18/21828/3131.04 (0.56–1.94)0.8964/7642/4551.68 (0.58–4.85)0.33518/19128/3400.88 (0.47–1.64)0.689
 Retroperitoneal37/21848/3130.90 (0.57–1.43)0.65414/7671/4550.84 (0.45–1.57)0.58236/19149/3400.75 (0.47–1.20)0.226
 Mediastinum30/21859/3131.38 (0.86–2.22)0.18112/7677/4551.08 (0.56–2.08)0.82535/19154/3400.87 (0.55–1.38)0.546
 Other sites11/21814/3130.92 (0.41–2.07)0.8373/7633/4551.31 (0.38–4.50)0.6708/19117/3401.16 (0.49–2.75)0.734
Clinical stages
 I + II + 4s50/21873/3131.03 (0.69–1.54)0.87215/76108/4551.24 (0.68–2.24)0.48651/19172/3400.79 (0.53–1.18)0.257
 III + IV46/21875/3131.09 (0.72–1.64)0.68017/76104/4550.95 (0.54–1.69)0.86347/19174/3400.90 (0.60–1.35)0.599

Adjusted for age and gender.